The efficacy and safety of adrenergic blockade after burn injury: A systematic review and meta-analysis

Journal of Trauma and Acute Care Surgery

Volumn 80, Issue 1, 2016, Pages 146-155

  Flores, Orlando ^a   Stockton, Kellie ^b   Roberts, Jason A ^a,c   Muller, Michael J ^a,d   Paratz, Jennifer D ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Queensland Children's Medical Research Institute   (Australia)

^c GRIFFITH UNIVERSITY   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

A blockade; Adrenergic blockade; Burns; Hypermetabolism; Propranolol

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; HORMONE; INSULIN; MUSCLE PROTEIN; PROPRANOLOL;

ADIPOSE TISSUE; BETA ADRENERGIC RECEPTOR BLOCKING; BIBLIOGRAPHIC DATABASE; BODY COMPOSITION; BRONCHOSPASM; BURN; CARDIOVASCULAR RESPONSE; CINAHL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EMBASE; EVIDENCE BASED PRACTICE; GENE EXPRESSION; HEART OUTPUT; HUMAN; HYPOTENSION; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEAN BODY WEIGHT; LIVER SIZE; MEDLINE; MENTAL DISEASE; META ANALYSIS; METABOLIC RATE; METABOLISM; MORTALITY; MUSCLE ATROPHY; OVID; PERIPHERAL LEAN MASS; PNEUMONIA; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTING ENERGY EXPENDITURE; REVIEW; SEPSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TRUNK FAT; WEB OF SCIENCE; WEIGHT, MASS AND SIZE; WOUND HEALING; BURNS; DRUG EFFECTS; ENERGY METABOLISM; PATHOPHYSIOLOGY; PATIENT SAFETY; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; BURNS; ENERGY METABOLISM; HUMANS; PATIENT SAFETY; PROPRANOLOL;

EID: 84952717477     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000887     Document Type: Review

References (41)

1. PeckMD. Epidemiology of burns throughout the world. Part I: distribution and risk factors. Burns. 2011;37(7):1087-1100.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.
3. Vos T, FlaxmanAD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196.
4. Jeschke MG, Gauglitz GG, Kulp GA, Finnerty CC,Williams FN, Kraft R, Suman OE, Mlcak RP, Herndon DN. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One. 2011;6(7):e21245.
5. Wilmore DW, Long JM, Mason AD Jr, Skreen RW, Pruitt BA Jr. Catecholamines: mediator of the hypermetabolic response to thermal injury. Ann Surg. 1974;180(4):653-669.
6. Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J BiochemCell Biol. 2005;37(10):1948-1961.
7. Rojas Y, Finnerty CC, Radhakrishnan RS, Herndon DN. Burns: an update on current pharmacotherapy. Expert Opin Pharmacother. 2012;13(17):2485-2494.
8. Murphy KD, Lee JO, Herndon DN. Current pharmacotherapy for the treatment of severe burns. Expert Opin Pharmacother. 2003;4(3):369-384.
9. Oberbeck R, Kobbe P. Beta-adrenergic antagonists: indications and potential immunomodulatory side effects in the critically ill. Curr Med Chem. 2009;16(9):1082-1090.
10. Brown DA, Gibbons J, Honari S, Klein MB, Pham TN, Gibran NS. Propranolol dosing practices in adult burn patients: implications for safety and efficacy. J Burn Care Res. 2015.
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1-e34.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-1012.
13. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, Ambroz A. A method for assessing the quality of a randomized control trial. Control Clin Trials. 1981;2(1):31-49.
14. Akcay MN, Akcay G, Ozturk G. The effects of metformin and oral propranolol on insulin resistance in thermally injured patients. Pain Clinic. 2005;17(2):189-192.
15. Barrow RE, Wolfe RR, Dasu MR, Barrow LN, Herndon DN. The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly. Ann Surg. 2006;243(1):115-120.
16. Hart DW, Wolf SE, Chinkes DL, Lal SO, Ramzy PI, Herndon DN. Betablockade and growth hormone after burn. Ann Surg. 2002;236(4):450-456.
17. Herndon DN, Dasu MR, Wolfe RR, Barrow RE. Gene expression profiles and protein balance in skeletal muscle of burned children after betaadrenergic blockade. Am J Physiol Endocrinol Metab. 2003;285(4): E783-E789.
18. Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001; 345(17):1223-1229.
19. Herndon DN, Rodriguez NA, Diaz EC, Hegde S, Jennings K, Mlcak RP, Suri JS, Lee JO, Williams FN, Meyer W, et al. Long-term propranolol use in severely burned pediatric patients: a randomized controlled study. Ann Surg. 2012;256(3):402-411.
20. Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN. Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children. J Trauma. 2007;62(3):676-681.
21. Williams FN, Herndon DN, Kulp GA, Jeschke MG. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery. 2011;149(2):231-239.
22. Mohammadi AA, Bakhshaeekia A, Alibeigi P, Hasheminasab MJ, Tolide-ei HR, Tavakkolian AR, Mohammadi MK. Efficacy of propranolol in wound healing for hospitalized burn patients. J Burn Care Res. 2009;30(6): 1013-1017.
23. Morio B, Irtun O, Herndon DN, Wolfe RR. Propranolol decreases splanchnic triacylglycerol storage in burn patients receiving a highcarbohydrate diet. Ann Surg. 2002;236(2):218-225.
24. Greenhalgh DG, Saffle JR, Holmes JHt, Gamelli RL, Palmieri TL, Horton JW, Tompkins RG, Traber DL, Mozingo DW, Deitch EA, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res. 2007;28(6):776-790.
25. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003; 31(4):1250-1256.
26. Gibran NS, Wiechman S, Meyer W, Edelman L, Fauerbach J, Gibbons L, Holavanahalli R, Hunt C, Keller K, Kirk E, et al. American Burn Association consensus statements. J Burn Care Res. 2013;34(4):361-385.
27. Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F,Wolfe RR. Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Ann Surg. 1988;208(4):484-492.
28. Minifee PK, Barrow RE, Abston S, Desai M, Herndon DN. Improved myocardial oxygen utilization following propranolol infusion in adolescents with postburn hypermetabolism. J Pediatr Surg. 1989;24(8):806-810.
29. Breitenstein E, Chiolero RL, Jequier E, Dayer P, Krupp S, Schutz Y. Effects of beta-blockade on energy metabolism following burns. Burns. 1990; 16(4):259-264.
30. Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil. 1997;18(3):223-227.
31. Kulp GA, Herndon DN, Lee JO, Suman OE, Jeschke MG. Extent and magnitude of catecholamine surge in pediatric burned patients. Shock. 2010;33(4):369-374.
32. Smith A, Barclay C, Quaba A, Sedowofia K, Stephen R, Thompson M, Watson A, McIntosh N. The bigger the burn, the greater the stress. Burns. 1997;23(4):291-294.
33. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther. 2004;9(4):243-255.
34. Arbabi S, Ahrns KS, Wahl WL, Hemmila MR, Wang SC, Brandt MM, Taheri PA. Beta-blocker use is associated with improved outcomes in adult burn patients. J Trauma. 2004;56(2):265-269.
35. Brooks NC, Song J, Boehning D, Kraft R, Finnerty CC, Herndon DN, Jeschke MG. Propranolol improves impaired hepatic phosphatidylinositol 3-kinase/akt signaling after burn injury. Mol Med. 2012;18:707-711.
36. Herndon DN, Nguyen TT, Wolfe RR, Maggi SP, Biolo G, Muller M, Barrow RE. Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines. Arch Surg. 1994;129(12):1301-1304.
37. Jeschke MG, Chinkes DL, Finnerty CC, Kulp G, Suman OE, NorburyWB, Branski LK, Gauglitz GG, Mlcak RP, Herndon DN. Pathophysiologic response to severe burn injury. Ann Surg. 2008;248(3):387-401.
38. Branski LK, Norbury WB, Herndon DN, Chinkes DL, Cochran A, Suman O, Benjamin D, Jeschke MG. Measurement of body composition in burned children: is there a gold standard? JPEN J Parenter Enteral Nutr. 2010; 34(1):55-63.
39. Daniels SR, Morrison JA, Sprecher DL, Khoury P, Kimball TR. Association of body fat distribution and cardiovascular risk factors in children and adolescents. Circulation. 1999;99(4):541-545.
40. Romana-Souza B, Nascimento AP, Monte-Alto-Costa A. Low-dose propranolol improves cutaneous wound healing of burn-injured rats. Plast Reconstr Surg. 2008;122(6):1690-1699.
41. Zhang XJ, Meng C, Chinkes DL, Finnerty CC, Aarsland A, Jeschke MG, Herndon DN. Acute propranolol infusion stimulates protein synthesis in rabbit skin wound. Surgery. 2009;145(5):558-567.